Page 39 - Robert Kramer News Today : Breaking News, Live Updates & Top Stories | Vimarsana

POLITICO Get the POLITICO Pulse newsletter Email Sign Up By signing up you agree to receive email newsletters or updates from POLITICO and you agree to our privacy policy and terms of service. You can unsubscribe at any time and you can contact us here. This sign-up form is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply. Presented by Editor’s Note: POLITICO Pulse is a free version of POLITICO Pro Health Care's morning newsletter, which is delivered to our subscribers each morning at 6 a.m. The POLITICO Pro platform combines the news you need with tools you c...

Johnson & Johnson documented contamination risks at Baltimore plant months before vaccine doses were ruined By Christopher Rowland The Washington Post,Updated May 19, 2021, 11:46 a.m. Email to a Friend Robert Kramer, President and Chief Executive Officer of Emergent BioSolutions, speaks via videoconference during a hearing on Capitol Hill in Washington.Stefani Reynolds/Associated Press WASHINGTON - Johnson & Johnson documented contamination risks at a Baltimore biodefense plant in June 2020, seven months before a contamination problem ruined 15 million doses of coronavirus vaccine and deraile...

The U.S. government awarded the company a $628 million contract last year to help make coronavirus vaccines. Emergent did not immediately respond to CNBC's request for comment. The hearing Wednesday comes more than a month after the Biden administration put J&J in charge of the Baltimore plant after U.S. officials learned that Emergent, a federal contractor that had been making key ingredients for J&J and AstraZeneca, cross-contaminated ingredients for the two shots. "There are a significant number of doses that we've manufactured. Again, we manufacture the bulk drug substances," Kramer to...

The FDA is holding over 100 million Johnson & Johnson Covid-19 vaccine doses for further testing, Emergent CEO Robert Kramer told lawmakers Wednesday.

Emergent CEO: J&J vaccine production could resume in days Nathaniel Weixel © Getty Emergent CEO: J&J vaccine production could resume in days Emergent BioSolutions could resume manufacturing doses of Johnson & Johnson's coronavirus vaccine "within a matter of days," the company's CEO Robert Kramer told a House panel Wednesday. Democratic lawmakers on the House Coronavirus Crisis Subcommittee pressed Kramer on Emergent's ability to fix a host of manufacturing issues identified by a Food and Drug Administration (FDA) inspection of its Baltimore facility in April. At least one ...